Drugs / Bivatuzumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02204046 | Jan 2000 → Feb 2001 | adenocarcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02204059 | Dec 1999 → Feb 2001 | non-small cell lung carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bivatuzumab | “186 Re-labelled bivatuzumab” NCT02204059 ↗1“Generic Name: Bivatuzumab” NCT02204046 ↗ |
| Known as | BIWA 4 | “Bivatuzumab: 186 Re-labelled humanised monoclonal antibody BIWA 4” NCT02204059 ↗1“186Re-labelled humanised monoclonal antibody BIWA 4” NCT02204046 ↗ |
| Modality | Monoclonal antibody | “186Re-labelled humanised monoclonal antibody BIWA 4” NCT02204046 ↗ |
| Route | Intravenous | “intravenously (i.v.) administered 186Rhenium (186Re)-labelled bivatuzumab” NCT02204046 ↗ |
| Target | CD44 | “CD44 antigen binding agent” CHEMBL2108413 ↗ |